High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
SOUL Findings Highlight Cardiovascular Benefits Beyond Glycemic Control With Oral GLP-1
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.